Trevena, Inc.

TRVN

US89532E2081

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:30:00 22/05/2024 BST			5-day change	1st Jan Change
0.4077 ^USD	-0.56%		-2.95%	-43.54%

05-16	HC Wainwright Adjusts Price Target on Trevena to $5 From $9, Maintains Buy Rating	MT
05-15	Earnings Flash (TRVN) TREVENA Reports Q1 Revenue $20,000	MT

Trevena, Inc. Announces the Resignation of David Soergel as Chief Medical Officer

July 20, 2017 at 08:33 pm

Trevena, Inc. announced that its chief medical officer, David Soergel, M.D., is planning to depart from the company in late August to pursue a new opportunity.

Latest news about Trevena, Inc.

HC Wainwright Adjusts Price Target on Trevena to $5 From $9, Maintains Buy Rating	05-16	MT
Earnings Flash (TRVN) TREVENA Reports Q1 Revenue $20,000	05-15	MT
Trevena, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-15	CI
Trevena, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-01	CI
Trevena, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	04-01	CI
Trevena, Inc. Promotion of Barry Shin to the Position of Executive Vice President and Chief Operating Officer	02-01	CI
Trevena Raises $4 Million via Placement, Warrant Exercise	12-28	MT
Trevena, Inc. announced that it has received $1.945934 million in funding	12-27	CI
Trevena to Raise $4 Million From Private Placement, Warrants Exercise Agreements	12-27	MT
Trevena, Inc. announced that it expects to receive $1.945934 million in funding	12-26	CI
Trevena Inc. Receives OLINVYK Agreement with Premier, Inc	12-04	CI
Trevena Files $200 Million Mixed Shelf	12-04	MT
Trevena, Inc. Announces Acceptance of Abstract Examining the Use of Olinvyk in Patients with Acute Burn Injuries	11-30	CI
Transcript : Trevena, Inc., Q3 2023 Earnings Call, Nov 14, 2023	11-14
Trevena, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Earnings Flash (TRVN) TREVENA Posts Q3 Revenue $180,000	11-14	MT
North American Morning Briefing : Caution -2-	11-14	DJ
Trevena, Inc. Announces Board Changes	11-09	CI
Trevena, Inc. Announces Completion of Initial Analysis of Olinvyk Continuous Respiratory Monitoring Data from Volition Study	02/10/23	CI
Trevena, Inc. Announces Retirement of Michael Dougherty as A Member of the Board of Directors and as A Member of the Audit Committee, Effective as of September 14, 2023	18/09/23	CI
Transcript : Trevena, Inc. - Special Call	06/09/23
Top Premarket Gainers	06/09/23	MT
Trevena, Inc. Announces Preliminary TRV045 Data from Two Proof-Of-Concept Studies Evaluating S1pr Mechanism of Action and CNS Target Engagement	06/09/23	CI
Trevena, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23	CI
Earnings Flash (TRVN) TREVENA Reports Q2 Revenue $3M	14/08/23	MT

Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of medicines for patients with central nervous system (CNS) disorders. The Company has one approved product in the United States, OLINVYK (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Companyâs pipeline includes three differentiated investigational drug candidates: TRV045 for diabetic neuropathic pain and epilepsy, TRV250 for the acute treatment of migraine and TRV734 for maintenance treatment of opioid use disorder. TRV045 is a novel, highly selective sphingosine-1-phosphate subtype 1 (S1P1) receptor modulator being developed as a potential treatment for acute and chronic neuropathic pain secondary to diabetic peripheral neuropathy. TRV734 is a small molecule G-protein biased ligand of the mu opioid receptor (MOR).

Sector

Biotechnology & Medical Research

Calendar

07/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Trevena, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.4077 USD

Average target price

4 USD

Spread / Average Target

+881.11%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
TREVENA, INC.	-43.54%	7.47M
VERTEX PHARMACEUTICALS INCORPORATED	+9.99%	115B
REGENERON PHARMACEUTICALS, INC.	+12.01%	106B
BIONTECH SE	-3.07%	24.69B
ARGENX SE	-1.08%	21.97B
GENMAB A/S	-5.34%	19.27B
BEIGENE, LTD.	-6.90%	17.56B
WUXI APPTEC CO., LTD.	-39.36%	17.32B
NEUROCRINE BIOSCIENCES, INC.	+5.82%	14.03B
SAREPTA THERAPEUTICS, INC.	+33.05%	12.13B

Bio Therapeutic Drugs

Trevena, Inc.

Equities

TRVN

US89532E2081

Biotechnology & Medical Research

Trevena, Inc. Announces the Resignation of David Soergel as Chief Medical Officer

Latest news about Trevena, Inc.

Chart Trevena, Inc.

Company Profile

Income Statement Evolution

Ratings for Trevena, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs